CompletedNCT04276883
Dexmedetomidine for Agitation in Bipolarity
About this title
Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder
Read the official source — NCT04276883Researchers compared Sublingual film containing Dexmedetomidine (BXCL501) and placebo to find out how the approaches affected psychotic symptoms in people with bipolarity.
Medication studyAges 18–75United States
Understand this study
What did researchers investigate?
Researchers compared Sublingual film containing Dexmedetomidine (BXCL501) and placebo to find out how the approaches affected psychotic symptoms in people with bipolarity.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 14 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: February 24, 2020
- Recruitment status
- Completed
- Enrollment listed in the registry
- 380
- Sponsor
- BioXcel Therapeutics Inc
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT04276883
- Official title
Show the full official title
A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine Efficacy and Safety of BXCL501 In Agitation Associated With Bipolar Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Little Rock · Cerritos · Culver City
12 more locations
- Long Beach
- Orange
- Miami Lakes
- Chicago
- Gaithersburg
- Las Vegas
- Berlin
- Marlton
- Charleston
- Austin
- DeSoto
- Richardson
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared Sublingual film containing Dexmedetomidine (BXCL501) and placebo to find out how the approaches affected psychotic symptoms in people with bipolarity.
Who is behind this study?
The study sponsor is BioXcel Therapeutics Inc.
Did this study involve medication?
Yes. The study involved medication, including Sublingual film containing Dexmedetomidine (BXCL501) and Placebo Film.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.
